Pharmacologic Therapies for Obesity

被引：81

作者：

Kaplan, Lee M. ^{[1
,2
]}

机构：

[1] Massachusetts Gen Hosp, MGH Weight Ctr, Boston, MA 02114 USA

[2] Massachusetts Gen Hosp, Gastrointestinal Unit, Boston, MA 02114 USA

来源：

GASTROENTEROLOGY CLINICS OF NORTH AMERICA | 2010年 / 39卷 / 01期

关键词：

Obesity treatment; Pharmacology treatments obesity; Weight loss medication; WEIGHT-LOSS; LIFE-STYLE; COMBINATION THERAPY; DRUG-TREATMENT; PHARMACOTHERAPY; OVERWEIGHT; FENFLURAMINE; NALTREXONE; BUPROPION; MEDICATIONS;

D O I：

10.1016/j.gtc.2010.01.001

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

100201 [内科学];

摘要：

This article examines the transitions in pharmacological therapy for obesity. It reviews the current options approved by the Food and Drug Administration and several drugs approved for other indications that can be used to treat obesity as well. Because weight regulation is complex and redundant systems protect against perceived starvation, optimal treatment of obesity in individual patients will likely require different combinations of behavioral, nutritional, pharmacologic, endoscopic, and surgical therapies.

引用

页码：69 / +

页数：12

共 39 条

[1]

Topiramate: A new potential pharmacological treatment for obesity [J].

Astrup, A ;

Toubro, S .

OBESITY RESEARCH, 2004, 12 :167S-173S

[2]

Lifestyle and Pharmacological Approaches to Weight Loss: Efficacy and Safety [J].

Bray, George A. .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2008, 93 (11) :S81-S88

[3]

Are non-prescription medications needed for weight control? [J].

Bray, George A. .

OBESITY, 2008, 16 (03) :509-514

[4]

Pharmacological treatment of the overweight patient [J].

Bray, George A. ;

Greenway, Frank L. .

PHARMACOLOGICAL REVIEWS, 2007, 59 (02) :151-184

[5]

Drug treatment of the overweight patient [J].

Bray, George A. ;

Ryan, Donna H. .

GASTROENTEROLOGY, 2007, 132 (06) :2239-2252

[6]

Medications for Weight Reduction [J].

Bray, George A. .

ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 2008, 37 (04) :923-+

[7]

Bariatric surgery: A systematic review and meta-analysis [J].

Buchwald, H ;

Avidor, Y ;

Braunwald, E ;

Jensen, MD ;

Pories, W ;

Fahrbach, K ;

Schoelles, K .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 292 (14) :1724-1737

[8]

Chakrabarti R, 2009, EXPERT OPIN THER TAR, V13, P195, DOI [10.1517/14728220802637063 , 10.1517/14728220802637063]

[9]

Valvular heart disease associated with fenfluramine-phentermine [J].

Connolly, HM ;

Crary, JL ;

McGoon, MD ;

Hensrud, DD ;

Edwards, BS ;

Edwards, WD ;

Schaff, HV .

NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (09) :581-588

[10]

Regression and progression of valvulopathy associated with fenfluramine and phentermine [J].

Dahl, CF ;

Allen, MR .

ANNALS OF INTERNAL MEDICINE, 2002, 136 (06) :489-489

← 1 2 3 4 →